Expert Sparring over Xarelto: Califf and Nissen Clash
This article was originally published in RPM Report
Executive Summary
An intriguing subplot in the September 8 advisory committee review of FDA’s Xarelto review was the verbal jousting between two high-visibility figures in the world of cardiovascular drug testing and drug therapy: Robert Califf (Vice-chancellor-clinical research at Duke and a principal investigator on the key Xarelto study, ROCKET-AF) and Steve Nissen (chair-cardiovascular medicine at the Cleveland Clinic).
You may also be interested in...
Transition Time: CMS Deputy Slavitt Takes Over As Interim Agency Head; FDA Enters Caretaker Phase Next
Andy Slavitt will be the caretaker head of CMS for the remainder of the Obama Administration, reinforcing the focus on smooth operations and close alignment with the White House health team. Duke’s Robert Califf joins FDA as Deputy Commissioner for Medical Products just in time for that agency to enter the caretaker phase.
What Does Nissen Think Of Califf’s Move To FDA?
At one time, both eminent cardiovascular researchers were considered to head up the agency during the first Obama Administration. Now Duke’s Califf is becoming Deputy Commissioner.
Califf’s Trial Design Prescription: Less Randomization, More Transparency
FDA’s new deputy commissioner is expected to advocate for innovation in clinical studies; Duke cardiologist has led numerous trials, including pivotal Xarelto study and Vytorin outcomes trial.